8.66
-0.46%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Moleculin Biotech
From its filings with the US Securities and Exchange Commission
Moleculin Biotech is based in Houston, Texas and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker MBRX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $33.6m. At that date it held total assets of $22.1m and shareholders' equity of $15.0m.
We are a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name “naxtarubicin”, which we believe is a “next-generation” anthracycline and, with it, are conducting a pivotal Phase 3 trial in combination with cytarabine for the treatment of subjects with relapsed/refractory (R/R) acute myeloid leukemia (AML). We call this the “MIRACLE” trial (derived from Moleculin R/R AML AnnAraC Clinical Evaluation). A blinded preliminary data readout has been released for the MIRACLE trial, and we expect to have an interim unblinding of data in mid-2026 and an additional unblinding in the second half of 2026, thereby concluding Part A of the two-part trial. We believe such early visibility for a pivotal registration-enabling trial is unique in that stakeholders will receive preliminary safety and efficacy data long before the conclusion of the trial.
We have two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. One of these portfolios has an ongoing investigator-initiated trial, another one planned and additional active preclinical testing. Since our inception, drug candidates from each of the three core portfolios are in active planning for, have approval to begin, are currently in or have successfully completed eighteen clinical trials.
Quoted from its 10-K, filed 18 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 2 Jun 2016
- Employees
- 17
- Website
- moleculin.com ↗
- Head office
- 5300 MEMORIAL DRIVE, HOUSTON, TX, 77007
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Walter KlempChairman of the Board, President, Chief Executive Officer, since 2015$1.5m
- Mr. Jonathan FosterChief Financial Officer, Executive Vice President$989,639
- Dr. Donald PickerChief Scientific Officer$694,062
- Mr. Michael CannonIndependent Director$79,300
- Ms. Elizabeth CermakIndependent Director$74,300
- Mr. John ClimacoIndependent Director$94,300
- Mr. Robert GeorgeIndependent Director$85,800
- Dr. Joy YanIndependent Director$57,800
- Ms. Jenene ThomasInvestor Relations, since 2021
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Moleculin Biotech Inc focuses on clinical-stage pharmaceuticals for cancer treatment with Annamycin for AML and lung metastases.
- The company has multiple drug candidates including WP1066 targeting brain tumors and pancreatic cancer through p-STAT3 inhibition.
- Moleculin Biotech employs 17 full-time employees in Houston, Texas, operating within the Health Care sector.
Weaknesses
- Moleculin Biotech has only 17 employees, indicating limited operational capacity for a clinical-stage biotech firm.
- The company's drug candidates are still in clinical stages without approved treatments for AML or other cancers.
- Moleculin Biotech's IPO in 2016 has not yet led to significant commercial success or revenue generation.
Opportunities
- Moleculin Biotech can expand its clinical-stage drug pipeline with additional immune/transcription modulators for cancer treatment.
- The company may leverage WP1066's p-STAT3 inhibition mechanism for broader cancer applications beyond current trials.
- Moleculin Biotech can seek partnerships to accelerate development of WP1220 for cutaneous T-cell lymphoma treatment.
Threats
- Moleculin Biotech faces competition from other biotech firms developing similar cancer therapies in the Health Care sector.
- The clinical-stage status of all drug candidates poses regulatory and development risks for Moleculin Biotech.
- Moleculin Biotech's limited employee count may hinder its ability to manage multiple clinical trials simultaneously.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.